Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LHF-535 · 1 trial · 1 indication
Safety and tolerability
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | 450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days |
| Placebo | PLACEBO_COMPARATOR | Placebo to match LHF-535 given once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| LHF-535 | DRUG | Oral suspension administered once daily for 14 days |
Inclusion Criteria: * Male or female 18 to 50 years of age, inclusive, at the time of screening * Able to understand the requirements of the study, to provide written informed consent (as evidenced by signature on an informed consent document that is approved by a Human Research Ethics Committee \[...
LHF-535 is an investigational small molecule being developed by TuHURA Biosciences, Inc. (NASDAQ: HURA). It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and it is not yet approved by the FDA.
LHF-535 is being studied for use in healthy participants. It has undergone a Phase 1 clinical trial to evaluate its safety and tolerability. The drug is investigational and has not been approved for any medical condition.
LHF-535 is being developed by TuHURA Biosciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol HURA. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics.
LHF-535 is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy participants. The drug is investigational and has not received FDA approval.
LHF-535 has been studied in a completed Phase 1 clinical trial with the identifier NCT03993704. This was a multiple ascending oral dose 14-day trial conducted in healthy participants in Australia, enrolling 24 individuals.
LHF-535 is a distinct investigational drug candidate developed by TuHURA Biosciences. No alternative names for LHF-535 have been reported in the clinical trial information.